Provention will wait for FDA to 'opine' on new data after teplizumab rejection, eyes Q4 for further talks

Provention Bio is being optimistic about the chances of resubmitting the rejected Type 1 diabetes asset teplizumab after the biotech's shares took a battering on the FDA’s recent complete response letter.